✦ LIBER ✦

Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass

✍ Scribed by R. W. Downs; A. M. Moffett; A. Ghosh; D. A. Cox; S. A. Dowsett; K. Harper

Publisher: Springer-Verlag
Year: 2009
Tongue: English
Weight: 210 KB
Volume: 21
Category: Article
ISSN: 0937-941X
DOI: 10.1007/s00198-009-1060-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Arzoxifene versus raloxifene: effect on

Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis

✍ D. L. Kendler; S. Palacios; D. A. Cox; J. Stock; J. Alam; S. A. Dowsett; J. Zanc 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 250 KB

Inhibitory effect of ipriflavone on vert

Inhibitory effect of ipriflavone on vertebral bone mass loss in postmenopausal women with low bone mass

✍ G. F. Mazzuoli 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 133 KB

Effects of 1-year treatment with iprifla

Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass

✍ M. Valente; L. Bufalino; G. N. Castiglione; R. D'Angelo; A. Mancuso; P. Galoppi; 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 368 KB

Effect of chronic treatment with iprifla

Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass

✍ C. Gennan 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 99 KB

Effect of chronic treatment with iprifla

Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass

✍ C. Gennari; S. Adami; D. Agnusdei; L. Bufalino; R. Cervetti; G. Crepaldi; C. Di 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 486 KB

Effects of bazedoxifene on bone mineral

Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal japanese women with osteoporosis

✍ Akira Itabashi; Kousei Yoh; Arkadi A Chines; Takami Miki; Masahiko Takada; Hiros 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 244 KB 👁 2 views

## Abstract This randomized, double‐blind, placebo‐controlled, dose‐response late phase 2 study evaluated the efficacy and safety of bazedoxifene in postmenopausal Japanese women 85 years of age or younger with osteoporosis. Eligible subjects received daily treatment with oral doses of bazedoxifene